This Week in Dermatology — Aug 28, 2026

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic drug safety and the cardiometabolic interface, new targeted therapy data in inflammatory and neutrophilic skin disease, risk stratification in skin cancer, and a pair of papers that together make a strong case for looking below the neck in acne. Let's dive in.

We start with the cardiometabolic theme, because the Journal of the American Academy of Dermatology has published a two-part continuing education series that essentially asks dermatologists to think like internists. Part one, from Zhou and colleagues, covers the traditional systemic agents — retinoids and rexinoids, anthracyclines, antifungals, oral minoxidil, methotrexate, phototherapy and colchicine — and lays out both the harms and the protective signals, with practical guidance on baseline workup and monitoring [1]. The practical message is that some of these drugs warrant preventive co-medication and structured lipid and blood pressure follow-up, not just a single baseline panel. Part two extends this to targeted and biologic therapy, including immune checkpoint inhibitors, antitumour monoclonal antibodies, intravenous immunoglobulin, Janus kinase inhibitors, tumour necrosis factor inhibitors, interleukin inhibitors and apremilast [2]. Here the picture cuts both ways: certain agents are linked to major adverse cardiovascular events and adverse lipid shifts and require baseline and on-treatment monitoring, while others may reduce systemic inflammation and atherogenic burden and could plausibly lower cardiometabolic risk. The authors are careful to say that the protective side of that ledger is not proven — randomised trials in dermatological populations are still needed. What you can act on now is the monitoring framework and the habit of co-managing high-risk patients with cardiology, endocrinology or primary care rather than owning that risk alone.

Staying with systemic therapy, JAMA Dermatology reports a prespecified secondary analysis of the phase three VALOR trial of brepocitinib, a first-in-class oral selective TYK2 and JAK1 inhibitor, in dermatomyositis [3]. This was a 52-week, double-blind, placebo-controlled trial across 90 sites in 20 countries enrolling 241 adults with active skin and muscle disease, and the analysis led by Mangold focuses on the cutaneous outcomes that matter most in our clinics. At the 30 milligram dose, brepocitinib separated from placebo on the Cutaneous Dermatomyositis Disease Area and Severity Index activity score as early as week four, and roughly a third of patients achieved a clinically meaningful cutaneous response compared with under a fifth on placebo. Itch remission was reached by close to two in five patients on active drug versus about one in five on placebo, and skin-related quality of life on Skindex-16 improved substantially more with treatment. Among the 155 participants with moderate to severe skin disease at baseline, close to half OF THOSE PATIENTS on the higher dose were clear or almost clear at week 52, and a similar proportion reached functional skin remission, roughly double the placebo rate. Safety was consistent with approved JAK and TYK2 inhibitors. For a disease where the rash is often the most refractory and most distressing component, this is meaningful evidence that an oral agent can deliver remission-level skin control that holds for a year.

Also in the systemic therapy space, Acta Dermato-Venereologica publishes a pan-European modified Delphi consensus on tildrakizumab dosing in moderate-to-severe plaque psoriasis, led by Maul, with 72 experienced dermatologists across nine countries voting on 48 statements and reaching agreement on 35 of them [4]. The resulting guidance is pragmatic: consider starting at 100 milligrams in biologic-naive patients with moderate disease who weigh under 90 kilograms with a body mass index under 25, and start at 200 milligrams in those at or above 90 kilograms or with a body mass index of 25 or higher, in severe disease, in high-impact-area involvement in the context of severe disease, after prior interleukin-23 p19 inhibitor failure, or after failure of two or more biologics. Up-titration is reasonable for suboptimal response, and down-titration back to 100 milligrams can be considered after at least a year of sustained remission. This is expert opinion rather than trial data, but it gives you a defensible framework for a decision that has been largely idiosyncratic.

The second theme is risk stratification and tailored management in harder cases. In the Journal of the American Academy of Dermatology, Ratner and colleagues report validation of an integrated 40-gene expression profile for high-risk cutaneous squamous cell carcinoma, combining the gene signature with five clinicopathologic features — immunosuppression, location, differentiation, tumour diameter, and perineural invasion — into four risk classes [5]. In a validation cohort of 572 patients the test significantly stratified both metastatic and local recurrence risk, with a negative predictive value above 95 percent for the lowest-risk class across National Comprehensive Cancer Network subsets. About 13 percent of patients fell into the highest-risk class, whose three-year metastasis-free survival was roughly two thirds, and it was that group that showed benefit from adjuvant radiation. On multivariable analysis the integrated result outperformed individual clinicopathologic factors. This is retrospective, so it is a decision-support tool rather than a mandate, but it speaks directly to the twin problems of undertreating aggressive tumours and irradiating patients who do not need it. Alongside that, the same journal offers a clinical review from Nukaly and Elston proposing a comorbidity-guided framework for pyoderma gangrenosum — tumour necrosis factor inhibition for inflammatory bowel disease-associated cases, interleukin-1 blockade for autoinflammatory syndromes, and JAK inhibition where inflammatory arthritis overlaps [6]. Across the studies and real-world reports they synthesise, matching the biologic to the systemic driver was associated with higher healing rates and fewer relapses than empiric therapy. It is a narrative review, not a trial, but as a way to organise your first-line choice in a disease with no good algorithm, it is useful.

Also in this practical vein, a clinical review in the same journal from Dreifus and colleagues addresses laser and energy-based devices in Fitzpatrick types four through six, where epidermal melanin competes as a chromophore and raises the risk of post-inflammatory hyperpigmentation, hypopigmentation, blistering and scarring [8]. Their synthesis favours low-fluence Q-switched and picosecond neodymium-YAG lasers for pigmentary disorders and tattoo removal, supports non-ablative fractional resurfacing with conservative settings, and flags ablative modalities as carrying higher complication rates. Sequential lower-energy sessions and strict photoprotection remain central. The honest conclusion is that large prospective trials in darker skin types simply do not exist yet.

The third theme is access and the acne we routinely miss. JAMA Dermatology publishes a cross-sectional survey led by Freeman covering 194 World Health Organization member states, with responses from 158 countries representing 97 percent of the world's population [7]. Global dermatologist density averaged about 2.7 per 100,000, ranging from roughly 0.4 in low-income countries to about 5 in high-income countries, with an estimated 175,000 dermatologists worldwide. Using countries that report adequate access to set a benchmark, the sufficiency threshold was about 5.6 dermatologists per 100,000 — and only 17 percent of countries met it. About one in five countries has no dermatology training programme at all, roughly four in five dermatologists practise in urban centres, and 42 percent of countries described access as inadequate or extremely poor. Notably, primary care physicians were cited as often as dermatologists as the main providers of skin care, with nurses, pharmacists and traditional healers carrying substantial load. That reframes upskilling front-line workers from a nice-to-have to a core equity strategy.

Finally, two papers converge on truncal acne. Acta Dermato-Venereologica reports a 20-country survey of 1,879 adults with physician-diagnosed acne, led by Rocha, in which truncal involvement was independently associated with stigmatisation, hospitalisation and poorer treatment adherence after adjustment for age, sex and country [9]. Stigmatisation was essentially identical in truncal-only and combined facial-and-truncal disease, close to half OF PATIENTS in each group, which argues that the burden is intrinsic to trunk involvement rather than a spillover from facial disease. Truncal-only patients had notably lower dermatologist access — about 64 percent versus 79 percent — yet higher hospitalisation and surgical consultation rates, which suggests they are being routed to the wrong doors. Complementing that, Clinical and Experimental Dermatology publishes an open-label randomised trial from Das and colleagues in 78 patients with mild to moderate truncal acne comparing ozenoxacin 2 percent lotion with clindamycin 1 percent lotion, both twice daily for 12 weeks on a background of nightly adapalene [10]. Both arms improved significantly on investigator global assessment, lesion counts and quality-of-life scores, with no significant difference between them and only mild transient adverse effects. Ozenoxacin, a non-fluorinated quinolone with minimal systemic absorption, is therefore a reasonable topical alternative where clindamycin resistance is a concern — though this was open-label and small, so it establishes comparability rather than superiority.

If you only have time for one paper this week, make it the brepocitinib skin outcomes analysis from VALOR in JAMA Dermatology [3]. Refractory dermatomyositis skin disease is one of the hardest problems in medical dermatology, and this is the first phase three evidence that a single oral agent can deliver durable, remission-level cutaneous control alongside itch and quality-of-life gains.

Here are the key takeaways from this week in Dermatology. First, build cardiometabolic screening and monitoring into your systemic and biologic prescribing, and share the risk with cardiology, endocrinology or primary care rather than carrying it alone. Second, brepocitinib at 30 milligrams produced rapid and sustained skin clearance in dermatomyositis, with roughly double the placebo rate of functional skin remission at a year in those with moderate to severe rash. Third, in psoriasis, tildrakizumab dose selection now has a consensus framework built around weight, body mass index, disease severity and prior biologic failure, with up- and down-titration both on the table. Fourth, the integrated 40-gene expression profile identifies the small subset of high-risk squamous cell carcinomas most likely to benefit from adjuvant radiation, and reassures you about the lowest-risk class. And fifth, examine the trunk in every acne consultation — truncal disease independently tracks with stigma, worse adherence and more hospital use, and topical ozenoxacin plus adapalene performed on par with clindamycin plus adapalene over 12 weeks.

That's your roundup for This Week in Dermatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague — in any specialty — who never has time to keep up with the literature. Tell them about AudioScholar: a free ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.